Make an Inquiry
Accelerating Spinal Muscular Atrophy Drug Development

Spinal muscular atrophy (SMA) presents a complex therapeutic challenge, demanding targeted innovation and rigorous scientific advancement. Protheragen stands at the forefront of SMA drug development, offering specialized expertise and a proven track record in advancing novel therapeutics for this debilitating neuromuscular disorder. Protheragen delivers comprehensive preclinical solutions spanning target validation, lead optimization, and IND-enabling studies, all tailored to the unique requirements of SMA research. Our integrated platforms combine state-of-the-art molecular biology, pharmacology, and translational science to ensure robust data and actionable insights at every stage of development. Backed by a multidisciplinary team with deep disease area knowledge, Protheragen leverages advanced in vitro and in vivo models, cutting-edge screening technologies, and stringent regulatory compliance to de-risk and accelerate drug candidates toward clinical readiness. With an unwavering commitment to scientific excellence and innovation, Protheragen partners with biopharmaceutical companies and research organizations to drive the development of transformative SMA therapies—bringing hope and improved outcomes to patients faster.

What is Spinal Muscular AtrophyTargets for Spinal Muscular AtrophyDrug Discovery and Development ServicesWhy Choose Us

What is Spinal Muscular Atrophy

Spinal Muscular Atrophy (SMA) is a hereditary neuromuscular disorder caused primarily by homozygous deletions or mutations in the SMN1 gene on chromosome 5q13. This genetic defect leads to insufficient production of the survival motor neuron (SMN) protein, which is essential for the maintenance and function of motor neurons in the spinal cord and lower brainstem. The resulting SMN protein deficiency causes progressive degeneration of these neurons, impairing their ability to transmit signals to skeletal muscles and ultimately leading to muscle weakness and atrophy. The severity of SMA varies depending on the residual SMN protein level, with forms ranging from severe prenatal onset to mild adult-onset disease. Clinically, SMA is characterized by symmetrical proximal muscle weakness, hypotonia, and delayed motor milestones, with the most severe types presenting in infancy and milder forms manifesting in childhood or adulthood. Diagnosis relies on clinical evaluation, family history, and confirmation by genetic testing for SMN1 gene mutations or deletions, often supplemented by SMN2 copy number analysis to assess disease severity. Treatment options have advanced significantly, including risdiplam (an oral SMN2 splicing modifier), nusinersen (an intrathecal antisense oligonucleotide), and onasemnogene abeparvovec (a gene therapy delivering functional SMN1), all aimed at increasing SMN protein levels and improving patient outcomes.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
img-1825352-65-5-risdiplam-rec-inn-usan risdiplam (Rec INN; USAN) 1825352-65-5 C22 H23 N7 O 401.464
onasemnogene abeparvovec (Prop INN; Rec INN; USAN); onasemnogene abeparvovec-xioi 1922968-73-7
nusinersen (Rec INN; USAN) 1258984-36-9

Learn More

Targets for Spinal Muscular Atrophy

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
survival of motor neuron 2, centromeric SMN2
Survival of motor neuron (SMN) complex
survival of motor neuron 1, telomeric SMN1
AMP-activated protein kinase (AMPK)
Glycogen synthase kinase 3 (GSK-3) (nonspecified subtype)
Gamma-Aminobutyric Acid
histone deacetylase 1 HDAC1
acylaminoacyl-peptide hydrolase APEH
Skeletal muscle troponin
troponin I2, fast skeletal type TNNI2

The principal therapeutic targets in Spinal Muscular Atrophy (SMA) are the SMN1 and SMN2 genes, which encode the Survival of Motor Neuron (SMN) protein. SMN1 is the primary source of full-length, functional SMN protein, essential for the assembly of small nuclear ribonucleoproteins (snRNPs) and the maintenance of motor neuron health. Mutations or deletions in SMN1 lead to a deficiency of SMN protein, impairing RNA splicing and causing motor neuron degeneration. SMN2, a nearly identical paralog, differs by a single nucleotide in exon 7, resulting in most transcripts producing a truncated, unstable protein. However, a small proportion of SMN2 transcripts generate functional SMN protein, making SMN2 copy number a critical modifier of disease severity and a key therapeutic focus. Therapeutic strategies for SMA target these molecular mechanisms by either replacing the defective SMN1 gene or modulating SMN2 splicing to enhance production of full-length SMN protein. Gene replacement therapies, such as onasemnogene abeparvovec, directly restore SMN1 function, while splicing modulators like nusinersen and risdiplam increase the inclusion of exon 7 in SMN2 transcripts. These approaches have demonstrated significant clinical benefits, transforming SMA from a fatal disorder into a treatable condition. Ongoing research continues to refine these therapies and explore additional targets involved in SMN protein regulation and motor neuron survival, with SMN1 and SMN2 remaining the most validated and impactful targets for current and future SMA treatments.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates Spinal Muscular Atrophy (SMA) drug discovery by providing robust screening and characterization platforms. We utilize advanced biochemical and cell-based assays, including ELISA, EIA, chemiluminescent, and fluorescent methods, to quantify key biomarkers such as SMN protein and assess COX-2 inhibition. Using human and recombinant materials, we measure IC-50 values to determine compound potency and therapeutic potential. This comprehensive approach enables precise evaluation of candidate drugs, guiding lead optimization and selection, and supports the development of effective SMA therapies by delivering actionable, high-quality data for informed decision-making.

Prostaglandin-Endoperoxide Synthase 2

Learn More

Why Choose Us

Choosing Protheragen means partnering with a team that possesses deep, specialized expertise in Spinal muscular atrophy research and drug development. At Protheragen, our highly skilled professionals are dedicated to advancing novel therapeutics for Spinal muscular atrophy, leveraging years of experience and a profound understanding of the disease’s complexities. We utilize state-of-the-art technology platforms and innovative methodologies to ensure the most effective and efficient preclinical drug development processes. Protheragen has built a strong track record of reliability, consistently delivering high-quality preclinical services that meet the evolving needs of our partners. Our rigorous commitment to quality standards and full regulatory compliance ensures that every project aligns with the highest industry benchmarks, providing our clients with confidence and peace of mind. Above all, Protheragen is driven by a sincere commitment to improving the lives of those affected by Spinal muscular atrophy. We are dedicated to pushing the boundaries of therapeutic development and working collaboratively to bring promising new treatments closer to patients in need.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing drugs for Spinal Muscular Atrophy (SMA)?

A: Preclinical research for SMA faces several unique challenges, including the selection of appropriate animal models that accurately recapitulate the human disease phenotype, particularly the genetic and neuromuscular aspects. Additionally, SMA is a rare disease, so sourcing sufficient biological materials and establishing robust endpoints for efficacy and safety can be complex. Our company addresses these challenges by utilizing validated SMA animal models, optimizing study designs, and leveraging advanced molecular and behavioral assays to ensure translational relevance.

Q: What are the key regulatory considerations during preclinical drug development for SMA?

A: Regulatory agencies such as the FDA and EMA require comprehensive preclinical data demonstrating safety, pharmacokinetics, and proof-of-concept efficacy before clinical trials can commence. For SMA, regulators may also require specific data on biodistribution, central nervous system (CNS) penetration, and long-term toxicity, especially for gene and RNA-targeted therapies. Our team is experienced in designing preclinical packages that meet or exceed regulatory expectations, and we provide guidance on preparing IND-enabling studies tailored to SMA drug candidates.

Q: What technical aspects are critical for successful preclinical research in SMA drug development?

A: Critical technical aspects include the use of genetically engineered SMA models, precise delivery of therapeutics to the CNS, and sensitive assays for measuring motor function, SMN protein levels, and neuromuscular integrity. Our laboratories are equipped with advanced imaging, molecular biology, and behavioral testing platforms specifically validated for SMA research, ensuring high-quality and reproducible data to support downstream development.

Q: What are the typical timeline and cost considerations for preclinical development of SMA therapeutics?

A: Preclinical development timelines for SMA therapeutics can range from 18 to 36 months, depending on the complexity of the drug modality and the extent of required studies. Costs vary accordingly, with gene therapies and biologics generally requiring higher investment due to specialized assays and longer-term safety studies. Our project management team works closely with clients to develop customized timelines and budgets, optimizing resources while maintaining compliance with regulatory standards.

Q: What are the main success factors for advancing SMA drug candidates through preclinical development?

A: Key success factors include early and rigorous validation of drug targets, selection of appropriate animal models, robust demonstration of efficacy and safety, and proactive regulatory engagement. Our integrated approach combines scientific expertise, state-of-the-art technology, and regulatory knowledge to de-risk preclinical programs and maximize the likelihood of successful transition to clinical development.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © 2025 Protheragen. All rights reserved.